Workflow
医美再生材料
icon
Search documents
打一针返老还童?童颜针卖了30亿
盐财经· 2025-07-14 09:33
Core Viewpoint - The article discusses the rapid growth and popularity of "童颜针" (youthful face injection) in the Chinese medical aesthetics market, highlighting its mechanism, market dynamics, and the competitive landscape among companies involved in this sector [6][8][22]. Market Growth - The market size of youthful face injections in China grew from approximately 100 million yuan in 2021 to over 3 billion yuan by 2024, representing a 30-fold increase in three years [6]. - Major companies like 长春圣博玛 and 爱美客 reported significant revenues from their youthful face injection products, with 长春圣博玛's "艾维岚" expected to generate over 4 billion yuan in revenue [6][24]. Product Dynamics - The core ingredient of most youthful face injections is 聚左旋乳酸 (PLLA), which stimulates collagen production in the skin [4][15]. - Different brands of youthful face injections vary in composition and pricing, with products like "濡白天使" priced around 10,000 yuan, while others like "艾塑菲" exceed 20,000 yuan [12][24]. Competitive Landscape - The entry of numerous pharmaceutical companies into the youthful face injection market has intensified competition, with over 20 companies currently registering products [30]. - The high profit margins associated with these products, with 爱美客 reporting a gross margin of 93.76% for gel-based injections, have attracted more players to the market [24][25]. Regulatory Environment - The approval of several youthful face injection products by the National Medical Products Administration (NMPA) has legitimized the market, with five products approved by 2024 [22][27]. Consumer Behavior - The article notes a growing trend among urban women to seek youthful face injections, driven by aggressive marketing and social media promotions [10][11]. - Despite the high costs, the demand for youthful face injections remains strong, with companies like 江苏吴中 achieving significant sales shortly after product launches [24][26]. Future Outlook - The global market for youthful face injections is projected to reach $1.545 billion by 2025, with a compound annual growth rate of approximately 3.8% from 2025 to 2033 [26]. - The competitive landscape is expected to evolve further, with potential price wars as more products enter the market [30].
王晔院长受邀出席 Juläine发布会,分享抗衰经验,闪耀国际舞台
Cai Fu Zai Xian· 2025-05-23 01:50
Core Insights - The collaboration between Saint Boma Group and Nordberg Medical aims to expand the global regenerative aesthetic market, highlighted by the launch of the Juläine PLLA facial filler in the Nordic region [1][2][4] - Saint Boma, a leader in the medical PLLA field, is leveraging its partnership with Nordberg Medical to innovate and apply regenerative material technology, enhancing its presence in the international aesthetic market [2][4] - The launch event attracted over 80 top aesthetic doctors from Sweden, Norway, Finland, and Iceland, showcasing a blend of technology and aesthetics in regenerative solutions [2][4] Group 1: Partnership and Market Position - The partnership between Saint Boma and Nordberg Medical began in 2017, focusing on localized research and production in Europe while adhering to global standards [4] - The successful launch of the Juläine brand in the Nordic region follows previous events in Spain and Italy, marking a significant step for Chinese aesthetic technology in the international market [4] - This strategic alliance exemplifies the combination of "Chinese manufacturing" and "Nordic standards," redefining the competitive landscape of the global regenerative aesthetic market [4] Group 2: Product and Innovation - Aivilan, the first NMPA-certified Class III medical device-grade PLLA facial filler from China, has rapidly become a phenomenon in the aesthetic field since its launch in 2021 [6] - Aivilan has disrupted traditional aesthetic market concepts by introducing the idea of "regenerative materials," leading to a shift in consumer perception from "changing appearance" to "natural self" [6] - The product has established itself as a high-end brand, inspiring other domestic companies to innovate and enhancing China's position in the global aesthetic industry [6] Group 3: Clinical Expertise and Global Influence - The event featured presentations from experts across Europe, with a highlight being Dr. Wang Ye's discussion on the precise application strategies of PLLA in skin anti-aging [8][10] - Dr. Wang's presentation provided valuable clinical insights and demonstrated Aivilan's unique treatment advantages in addressing facial laxity and contour issues, contributing to the global discourse on aesthetic treatments [10][12] - The event marked a significant moment for Chinese aesthetic experts to share clinical experiences with European counterparts, showcasing the potential for cross-regional knowledge exchange [12] Group 4: Future Outlook - Aivilan's emergence is reshaping the global aesthetic landscape, leading to a resurgence of previously marginalized products and a decline in traditional filler market share [14][15] - The company is poised to capitalize on unprecedented opportunities in the aesthetic market, similar to the electric vehicle industry's rapid growth [15] - Aivilan's international expansion will continue, with plans to enter Southeast Asia, South America, the Middle East, Japan, and the U.S., aiming for a comprehensive output of clinical standards and aesthetic philosophies [15]